News

The company expects to launch the nasal spray product in 2013. National registration processes, including price and reimbursement, will now follow in each country, the company said. Meda

Telotristat etiprate is an orally-delivered serotonin synthesis inhibitor (SSI) drug that acts to reduce serotonin levels. Lexicon chief medical officer and clinical development senior vice president Pablo Lapuerta

The company’s complete line of products provides weight-loss options for all consumers, including those looking to cleanse their system of toxins. Creative Bioscience executive director Ike Blackmon said

The product, a generic equivalent to Roche’s Boniva, is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Boniva had US sales of approximately $517m for

In RENAISSANCE 4 and RENAISSANCE 5, efficacy and tolerability studies, patients did not respond adequately to initial antidepressant treatment. The studies did not meet the primary endpoint of

The company expects to launch Altrazeal in six additional markets for human and veterinary use, in the near future. The company also expects to receive approval in the

The extension will allow the existing ten Nanobody programs to advance to a stage where Boehringer can progress each program into development. Ablynx will receive a total of

Both the parties will select between five and ten projects, decided on by a committee of UCB and Oxford University representatives, InPharm reported. UCB’s immunology research center currently

The randomized, open-label, dose-finding study will evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic poperties of the growth harmone. The trial will compare the 12-month growth velocity of